Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIFE-DSR Biomarker Sub-study
NCT06860373Phase 3Terminated
- Sponsor
- LuMind IDSC Foundation
- Start
- Jun 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of florquinitau in Alzheimer's disease (AD), sponsored by LuMind IDSC Foundation. Primary endpoints: Primary Outcome Measure to establish a biobank specifically for DS participants at Month 32 and Primary Outcome to ascertain the degree and distribution of tau pathology in DS as a function of age using tau PET at Month 32. Started Jun 2023; status: terminated.
02
Drugs
florquinitau
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06860373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860373.